Literature DB >> 29738697

Prognostic and clinical significance of histone deacetylase 1 expression in breast cancer: A meta-analysis.

Weiqiang Qiao1, Heyang Liu2, Ruidong Liu3, Qipeng Liu1, Ting Zhang1, Wanying Guo1, Peng Li1, Miao Deng4.   

Abstract

BACKGROUND: There are conflicting reports about the role of histone deacetylase 1 (HDAC1) in breast cancer prognosis. Here, we conducted a meta-analysis to investigate the prognostic significance of HDAC1 in breast cancer.
MATERIALS AND METHODS: We searched different databases to identify studies evaluating the association between HDAC1 expression and its prognostic value in breast cancer. The pooled hazard ratios (HRs) and odds radios (ORs) with 95% confidence intervals (95% CIs) were calculated from these studies to assess specific correlation.
RESULTS: Our meta-analysis of four databases identified 7 eligible studies with 1429 total patients. We found that HDAC1 over-expression did not correlate with disease-free survival (DFS) and overall survival (OS) in breast cancer. Subgroup analysis indicated an association between up-regulated HDAC1 expression and better OS (HR = 0.47, 95% CI: 0.23-0.97; P = 0.04) in Asian breast cancer patients. However, false-positive report probability (FPRP) analysis and trial sequential analysis (TSA) indicated that the results need further validation. Furthermore, HDAC1 over-expression was associated with positive estrogen receptor (ER) expression (OR, 3.30; 95% CI, 1.11-9.83; P = 0.03) and negative human epidermal growth factor receptor 2 (HER2) expression (OR, 1.79; 95% CI, 1.22-2.61; P = 0.003), but there were no significant differences between patients based on age, tumor size, lymph node metastasis, nuclear grade, or progesterone receptor (PR) expression.
CONCLUSION: Overall, our meta-analysis demonstrated an association between increased HDAC1 expression and better OS in Asian breast cancer patients. In addition, HDAC1 over-expression correlated with positive ER and negative HER2 expression in breast cancer. However, researches in large patients' randomised controlled trials (RCTs) are needed to confirm the results.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Breast cancer; HDAC1; Meta-analysis; Prognosis

Mesh:

Substances:

Year:  2018        PMID: 29738697     DOI: 10.1016/j.cca.2018.05.005

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  6 in total

Review 1.  The role of histone deacetylase 3 in breast cancer.

Authors:  Rezgar Rahbari; Yousef Rasmi; Mohammad Hassan Khadem-Ansari; Mohammad Abdi
Journal:  Med Oncol       Date:  2022-05-17       Impact factor: 3.064

2.  Association of HDAC8 Expression with Pathological Findings in Triple Negative and Non-Triple Negative Breast Cancer: Implications for Diagnosis.

Authors:  Mohammad-Nazir Menbari; Karim Rahimi; Abbas Ahmadi; Samira Mohammadi-Yegane; Anvar Elyasi; Nikoo Darvishi; Vahedeh Hosseini; Mohammad Abdi
Journal:  Iran Biomed J       Date:  2020-05-02

3.  The Impact of Androgen Receptor and Histone Deacetylase 1 Expression on the Prognosis of Ductal Carcinoma In Situ.

Authors:  Choong Man Lee; Il Yong Chung; Yangsoon Park; Keong Won Yun; Hwi Gyeong Jo; Hye Jin Park; Hee Jin Lee; Sae Byul Lee; Hee Jeong Kim; Beom Seok Ko; Jong Won Lee; Byung Ho Son; Sei Hyun Ahn; Jisun Kim
Journal:  J Breast Cancer       Date:  2020-12-24       Impact factor: 3.588

4.  Development and Validation of a Novel Histone Acetylation-Related Gene Signature for Predicting the Prognosis of Ovarian Cancer.

Authors:  Qinjin Dai; Ying Ye
Journal:  Front Cell Dev Biol       Date:  2022-02-18

5.  CREPT Disarms the Inhibitory Activity of HDAC1 on Oncogene Expression to Promote Tumorigenesis.

Authors:  Yajun Cao; Bobin Ning; Ye Tian; Tingwei Lan; Yunxiang Chu; Fangli Ren; Yinyin Wang; Qingyu Meng; Jun Li; Baoqing Jia; Zhijie Chang
Journal:  Cancers (Basel)       Date:  2022-09-30       Impact factor: 6.575

6.  Clinical significance of HDAC1, -2 and -3 expression levels in esophageal squamous cell carcinoma.

Authors:  Huiwu Li; Hui Li; Yibulayin Waresijiang; Yan Chen; Ying Li; Liang Yu; Yike Li; Ling Liu
Journal:  Exp Ther Med       Date:  2020-04-29       Impact factor: 2.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.